Template:Antibiotics Ludwigs Immunocompromised: Difference between revisions
No edit summary |
|||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
====Immunocompromised | ====Immunocompromised<ref>Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503</ref>==== | ||
*[[Cefepime]] 2 g IV q12 hrs + [[Metronidazole]] 500 mg IV q6 hrs OR | *[[Cefepime]] 2 g IV q12 hrs + [[Metronidazole]] 500 mg IV q6 hrs OR | ||
*[[Meropenem]] 1 g IV q8 hrs OR | *[[Meropenem]] 1 g IV q8 hrs OR | ||
*[[Imipenem/Cilastatin]] 500mg (20mg/kg) IV q6 hours | *[[Imipenem/Cilastatin]] 500mg (20mg/kg) IV q6 hours | ||
*[[Piperacillin-tazobactam]] 4.5g (80mg/kg) IV q6 hours | *[[Piperacillin-tazobactam]] 4.5g (80mg/kg) IV q6 hours | ||
*Add [[Vancomycin]] 15-20 mg/kg q8 hrs (max 2 g per dose) if concern for MRSA risk factors | *Add [[Vancomycin]] 15-20 mg/kg IV q8 hrs (max 2 g per dose) if concern for MRSA risk factors | ||
Latest revision as of 19:00, 23 June 2019
Immunocompromised[1]
- Cefepime 2 g IV q12 hrs + Metronidazole 500 mg IV q6 hrs OR
- Meropenem 1 g IV q8 hrs OR
- Imipenem/Cilastatin 500mg (20mg/kg) IV q6 hours
- Piperacillin-tazobactam 4.5g (80mg/kg) IV q6 hours
- Add Vancomycin 15-20 mg/kg IV q8 hrs (max 2 g per dose) if concern for MRSA risk factors
- ↑ Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503